In the BioHarmony Drug Report Database
Pergolide
Permax (pergolide) is a small molecule pharmaceutical. Pergolide was first approved as Permax on 1988-12-30. It is used to treat parkinson disease and tourette syndrome in the USA. It is known to target 5-hydroxytryptamine receptor 1B, alpha-2B adrenergic receptor, D(1B) dopamine receptor, D(4) dopamine receptor, 5-hydroxytryptamine receptor 2C, D(3) dopamine receptor, alpha-2C adrenergic receptor, 5-hydroxytryptamine receptor 1D, 5-hydroxytryptamine receptor 2A, alpha-2A adrenergic receptor, 5-hydroxytryptamine receptor 1A, D(1A) dopamine receptor, D(2) dopamine receptor, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 7, and 5-hydroxytryptamine receptor 6.
Trade Name
|
Permax |
|---|---|
Common Name
|
pergolide |
ChEMBL ID
|
CHEMBL531 |
Indication
|
parkinson disease, tourette syndrome |
Drug Class
|
Ergot alkaloid derivatives |
Image (chem structure or protein)